贝伐单抗联合化疗治疗晚期结直肠癌的效果研究
Effect of bevacizumab combined with chemotherapy on advanced colorectal cancer
张志红1
作者信息
- 1. 湖北公安县人民医院,湖北 荆州 434300
- 折叠
摘要
目的 分析贝伐单抗联合化疗治疗晚期结直肠癌的效果.方法 选取2015年3月～2016年12月本院收治的100例晚期结直肠癌患者为对象,随机分为甲组和乙组,每组50例.甲组给予常规化疗,乙组给予联合化疗与贝伐单抗治疗,对比分析2组患者的临床疗效.结果 甲组治疗总有效率为28.0％,乙组为54.0％,2组差异具有统计学意义(P<0.05).结论 联合化疗与贝伐单抗,治疗晚期结直肠癌,疗效显著,值得推广.
Abstract
Objective To evaluate the efficacy of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer. Methods 100 cases of patients with advanced colorectal cancer from March 2015 to December 2016 in our hospital were selected as the object, and randomly divided into observation group and control group, 50 cases in each group. Group A was given routine chemotherapy, group B was given combined with chemotherapy and bevacizumab treatment, compared the two groups of patients with clinical efficacy. Results The total effective rate was 28.0％, group B was 54.0％, the difference between the two groups was statistically significant (P<0.05). Conclusion Combined chemotherapy and bevacizumab is effective in the treatment of advanced colorectal cancer and is worthy of promotion.
关键词
贝伐单抗/化疗/晚期/结直肠癌Key words
bevacizumab/chemotherapy/advanced/colorectal cancer引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据